Gilead Sciences (GILD) Stock Buyback History
TTM buyback yield 0.93% · Shareholder yield (TTM) 0.93%.
GILD
TTM buyback yield
0.93%
Shareholder yield (TTM)
0.93%
5Y share count change
-0.6%
TTM buyback spend
$1.61B
SBC coverage (TTM)
3.54x
YoY change in spend
+67.1%
5Y CAGR of spend
+4.0%
Peak year (2016)
$11.00B
Cumulative spend
$51.21B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Gilead Sciences (GILD) repurchased about $1.61B of stock over the trailing twelve months.
- Diluted share count is roughly flat (-0.6%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
- TTM buyback ÷ stock-based-comp ratio of 3.54× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +4.0% per year over the latest 5-year window.
- TTM repurchases used about 26% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $1.92B | $0.00 | $1.92B | 1.25B | 0.0% | 1.26% |
| 2024 | $1.15B | $835.00M | $315.00M | 1.25B | -0.2% | 1.00% |
| 2023 | $1.00B | $766.00M | $234.00M | 1.26B | -0.3% | 0.99% |
| 2022 | $1.40B | $644.00M | $752.00M | 1.26B | 0.0% | 1.30% |
| 2021 | $546.00M | $635.00M | −$89.00M | 1.26B | -0.1% | 0.60% |
| 2020 | $1.58B | $643.00M | $940.00M | 1.26B | -1.1% | 2.17% |
| 2019 | $1.75B | $636.00M | $1.11B | 1.28B | -2.4% | 2.13% |
| 2018 | $2.90B | $845.00M | $2.06B | 1.31B | -0.8% | 3.59% |
| 2017 | $954.00M | $638.00M | $316.00M | 1.32B | -2.9% | 1.02% |
| 2016 | $11.00B | $380.00M | $10.62B | 1.36B | -10.7% | 11.67% |
| 2015 | $10.00B | $382.00M | $9.62B | 1.52B | -7.7% | 6.88% |
| 2014 | $5.35B | $360.00M | $4.99B | 1.65B | -2.8% | 3.77% |
| 2013 | $582.00M | $252.00M | $330.00M | 1.69B | 7.1% | 0.51% |
| 2012 | $667.00M | $209.00M | $458.00M | 1.58B | 0.1% | 1.20% |
| 2011 | $2.38B | $192.38M | $2.19B | 1.58B | -9.5% | 7.89% |
| 2010 | $4.02B | $200.04M | $3.82B | 1.75B | -6.5% | 13.73% |
| 2009 | $998.50M | $180.68M | $817.81M | 1.87B | -2.6% | 2.56% |
| 2008 | $1.97B | $153.36M | $1.82B | 1.92B | -0.6% | 4.23% |
| 2007 | $487.54M | $0.00 | $487.54M | 1.93B | 5.0% | 1.14% |
| 2006 | $544.94M | $0.00 | $544.94M | 1.84B | -3.2% | 1.84% |
| 2005 | $0.00 | $0.00 | $0.00 | 1.90B | 2.2% | — |
| 2004 | $0.00 | $0.00 | $0.00 | 1.86B | 15.4% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 1.61B | -2.6% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 1.65B | 2.1% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 1.62B | 11.1% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 1.46B | 6.3% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 1.37B | 4.4% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 1.31B | 26.2% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 1.04B | 17.0% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.89B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Gilead Sciences (GILD) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Gilead Sciences (GILD)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Gilead Sciences (GILD)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $1.92B | +67.1% | +$772.00M | ||
| 2024 | $1.15B | +15.0% | +$150.00M | ||
| 2023 | $1.00B | -28.4% | -$396.00M | ||
| 2022 | $1.40B | +155.7% | +$850.00M | ||
| 2021 | $546.00M | -65.5% | -$1.04B | ||
| 2020 | $1.58B | -9.5% | -$166.00M | ||
| 2019 | $1.75B | -39.7% | -$1.15B | ||
| 2018 | $2.90B | +204.0% | +$1.95B | ||
| 2017 | $954.00M | -91.3% | -$10.05B | ||
| 2016 | $11.00B | +10.0% | +$999.00M | ||
| 2015 | $10.00B | +87.0% | +$4.65B | ||
| 2014 | $5.35B | +819.1% | +$4.77B | ||
| 2013 | $582.00M | -12.7% | -$85.00M | ||
| 2012 | $667.00M | -72.0% | -$1.72B | ||
| 2011 | $2.38B | -40.8% | -$1.64B | ||
| 2010 | $4.02B | +302.9% | +$3.02B | ||
| 2009 | $998.50M | -49.3% | -$971.09M | ||
| 2008 | $1.97B | +304.0% | +$1.48B | ||
| 2007 | $487.54M | -10.5% | -$57.40M | ||
| 2006 | $544.94M | — | +$544.94M | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | — | $0 | ||
| 2003 | $0 | — | $0 | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | — | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | $0 | ||
| 1990 | $0 | — | — |
In 2025, Gilead Sciences (GILD) buyback spend totalled $1.92B – surged 67.1% year-over-year.
Through 2020–2025 (5 years), Gilead Sciences buyback spend delivered a +4.0% annualised rate; sustaining 2 straight years of year-over-year growth.
Gilead Sciences buyback spend plunged from $11.00B in 2016 to $1.92B in 2025, a 82.5% drawdown.
The highest annual buyback spend of $11.00B was reported in 2016. The lowest in the available history was $0 in 1990.
Gilead Sciences (GILD) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Gilead Sciences Buyback Spend 2025: $1.92B
Gilead Sciences buyback spend in 2025 was $1.92B, surged 67.1% from 2024.
Gilead Sciences Buyback Spend 2024: $1.15B
Gilead Sciences buyback spend in 2024 was $1.15B, grew 15.0% from 2023.
Gilead Sciences Buyback Spend 2023: $1.00B
Gilead Sciences buyback spend in 2023 was $1.00B, declined 28.4% below 2022.
Gilead Sciences Buyback Spend 2022: $1.40B
Gilead Sciences buyback spend in 2022 was $1.40B, surged 155.7% from 2021.
Gilead Sciences Buyback Spend 2021: $546.00M
Gilead Sciences buyback spend in 2021 was $546.00M.
See more financial history for Gilead Sciences (GILD).
Sector peers by buyback spend
Companies in the same sector as Gilead Sciences, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.54×.
Capital allocation mix
How Gilead Sciences splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $6.20B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Gilead Sciences's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Gilead Sciences buy back its own stock?
Yes, Gilead Sciences (GILD) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Gilead Sciences spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $1.61B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Gilead Sciences's buyback yield?
TTM buyback yield is about 0.93% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Gilead Sciences's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.93% combined (TTM-based where available).
Is Gilead Sciences diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Gilead Sciences's share count changed?
Diluted weighted average shares changed by about -0.6% over roughly five fiscal years (annual income statement data).
What is Gilead Sciences's buyback spend?
Latest reported buyback spend for Gilead Sciences (GILD) is $1.61B (period ending March 31, 2026).
How has Gilead Sciences buyback spend changed year-over-year?
Gilead Sciences (GILD) buyback spend changed +67.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Gilead Sciences buyback spend?
Gilead Sciences (GILD) buyback spend compound annual growth rate is +4.0% over the most recent 5 years available.
When did Gilead Sciences buyback spend hit its highest annual value?
Gilead Sciences buyback spend reached its highest annual value of $11.00B in 2016.
What was Gilead Sciences buyback spend in 2024?
Gilead Sciences (GILD) buyback spend in 2024 was $1.15B.
What was Gilead Sciences buyback spend in 2025?
Gilead Sciences (GILD) buyback spend in 2025 was $1.92B.
Explore more
GILD Overview
Company profile, financial tools, and key metrics
GILD Revenue Counter
Earns $942.86 every second. See per minute, hour, and day.
GILD Earnings Counter
Earns $292.24 per second net profit. See per minute, hour, and day.
GILD Economic Scale
Exceeds Bosnia and Herzegovina's GDP. Compare with world economies.
GILD What If Invested
What if you had invested $1,000? See historical returns from any date.
GILD How It Makes Money
Discover visual breakdown of $29.73B in revenue — where it comes from and where it goes.
GILD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
GILD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
GILD Daily Price Character
Explosive · 48.7% historical win rate (green days). Streaks & record days.
GILD Stock Split History
5 splits on record. Dates, ratios, and cumulative multiple.
GILD Dividend Profile
Yield: 2.44%. Safety: 8/8. See full history.
GILD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
GILD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
GILD Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
GILD Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.